Melissa Rasar Young, MD, PhD
Associate Professor of Therapeutic Radiology; Medical Director, Radiation Oncology Center, Smilow Cancer Hospital Care Center in New Haven, Therapeutic Radiology; Chief, Head and Neck Radiotherapy Program, Therapeutic Radiology
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal BrachytherapyLi J, Park H, Huang G, Young M, Ratner E, Santin A, Damast S. Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s138. DOI: 10.1016/j.ijrobp.2021.07.311.
- GSOR10 Presentation Time: 3:15 PM Single Implant Hybrid Interstitial Brachytherapy for Cervical Cancer during the COVID-19 Pandemic: An Institutional ApproachDamast S, Tien C, Young M, Altwerger G, Ratner E. GSOR10 Presentation Time: 3:15 PM Single Implant Hybrid Interstitial Brachytherapy for Cervical Cancer during the COVID-19 Pandemic: An Institutional Approach. Brachytherapy 2021, 20: s54. PMCID: PMC8215885, DOI: 10.1016/j.brachy.2021.06.086.
- PO03 A Novel Design in Peripheral Channels of a Brachytherapy Multichannel Applicator Demonstrates Significant Differences in Dose to Surrounding VolumeTien C, Damast S, Young M, Kaur M, Kim J, Chen Z. PO03 A Novel Design in Peripheral Channels of a Brachytherapy Multichannel Applicator Demonstrates Significant Differences in Dose to Surrounding Volume. Brachytherapy 2021, 20: s56-s57. DOI: 10.1016/j.brachy.2021.06.091.
- Cervical CancerLaird J, Young M, Damast S. Cervical Cancer. 2020 DOI: 10.1891/9780826155146.0028.
- Vulvar CancerLaird J, Young M, Damast S. Vulvar Cancer. 2020 DOI: 10.1891/9780826155146.0030.
- Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and NeckJacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.
- An Update on Trends and Disparities in Utilization of Total Laryngectomy: a Population-Based AnalysisJacobs D, Park H, Young M, Breen C, Rahmati R, Mehra S, Judson B. An Update on Trends and Disparities in Utilization of Total Laryngectomy: a Population-Based Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1145-1146. DOI: 10.1016/j.ijrobp.2019.11.214.
- Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality TreatmentLi J, Young M, Huang G, Litkouhi B, Santin A, Schwartz P, Damast S. Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s225. DOI: 10.1016/j.ijrobp.2019.06.318.
- Does Use of Bowel Prep Improve HDR Cervix Implant Dosimetry?Kassick M, Gao S, Park H, Kelly J, Young M, Tien C, Damast S. Does Use of Bowel Prep Improve HDR Cervix Implant Dosimetry? International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e324. DOI: 10.1016/j.ijrobp.2019.06.1808.
- Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical stagingHochreiter A, Kelly J, Young M, Litkouhi B, Black J, Stromberger C, Higgins S, Schwartz P, Damast S. Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging. Gynecologic Oncology 2019, 154: 287. DOI: 10.1016/j.ygyno.2019.04.674.
- Risks and patterns of paraaortic node metastasis after chemoradiotherapy for pelvic node-positive paraaortic node negative cervical cancer in the era of metabolic imagingHaines K, Hochreiter A, Young M, Damast S, Litkouhi B. Risks and patterns of paraaortic node metastasis after chemoradiotherapy for pelvic node-positive paraaortic node negative cervical cancer in the era of metabolic imaging. Gynecologic Oncology 2019, 154: 264. DOI: 10.1016/j.ygyno.2019.04.611.
- The Theoretical Benefits of a 15 Ci Ir-192 Source for HDR BrachytherapyTien C, Chen Z, Damast S, Young M, Carlson D. The Theoretical Benefits of a 15 Ci Ir-192 Source for HDR Brachytherapy. Brachytherapy 2019, 18: s25. DOI: 10.1016/j.brachy.2019.04.054.
- Does Rectosigmoid Contrast Negatively Affect HDR Cervix Brachytherapy Implant Dosimetry?Kassick M, Gao S, Young M, Tien C, Damast S. Does Rectosigmoid Contrast Negatively Affect HDR Cervix Brachytherapy Implant Dosimetry? Brachytherapy 2019, 18: s98-s99. DOI: 10.1016/j.brachy.2019.04.213.
- Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal BrachytherapyYoung M, Stahl J, Black J, Litkouhi B, Damast S. Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e656-e657. DOI: 10.1016/j.ijrobp.2018.07.1780.
- Image-Guided Multi-Channel Cylinder Brachytherapy for Gynecologic Cancers Involving the Vagina: Initial Experience with Vaginal Dose-Volume ParametersDamast S, Young M, Picone J, Kimmett J, Kaur M, Tien C. Image-Guided Multi-Channel Cylinder Brachytherapy for Gynecologic Cancers Involving the Vagina: Initial Experience with Vaginal Dose-Volume Parameters. Brachytherapy 2018, 17: s115-s116. DOI: 10.1016/j.brachy.2018.04.212.
- Early Experience with Brachytherapy Model-Based Dose Calculation Algorithm: Commissioning and Retrospective Comparison with Historical TemplateTien C, Damast S, Picone J, Young M, Chen Z. Early Experience with Brachytherapy Model-Based Dose Calculation Algorithm: Commissioning and Retrospective Comparison with Historical Template. Brachytherapy 2018, 17: s40-s41. DOI: 10.1016/j.brachy.2018.04.059.
- Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.Chang E, Mougalian S, Adelson K, Young M, Yu J. Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database. Journal Of Clinical Oncology 2018, 36: e13069-e13069. DOI: 10.1200/jco.2018.36.15_suppl.e13069.
- Extended Duration of Dilator Use Beyond 1 Year May Reduce Vaginal Stenosis After Intravaginal High-Dose-Rate BrachytherapyStahl J, Qian J, Park H, Tien C, Young M, Ratner E, Carlson D, Chen Z, Damast S. Extended Duration of Dilator Use Beyond 1 Year May Reduce Vaginal Stenosis After Intravaginal High-Dose-Rate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s228. DOI: 10.1016/j.ijrobp.2017.06.561.
- Patterns of Care and Outcomes of Patients With Breast Cancer Who Refuse Recommended TherapyJohnson S, An Y, Kelly J, Aneja S, Mougalian S, Young M, Moran M, Evans S. Patterns of Care and Outcomes of Patients With Breast Cancer Who Refuse Recommended Therapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e20-e21. DOI: 10.1016/j.ijrobp.2017.06.639.
- The Impact of Standardized Treatment Planning Guidelines on Treatment Plan QualityKelly J, Park H, Carlson D, Moran M, Wilson L, Young M, Higgins S, Guay D, Arthur G, Simmons W, Winter S, Evans S. The Impact of Standardized Treatment Planning Guidelines on Treatment Plan Quality. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e556. DOI: 10.1016/j.ijrobp.2017.06.1936.
- Who Benefits From Chemoradiation in Locally Advanced Endometrial Cancer? An Analysis of the National Cancer Data BaseLester-Coll N, Park H, Rutter C, Corso C, Young M, Ratner E, Litkouhi B, Decker R, Yu J, Damast S. Who Benefits From Chemoradiation in Locally Advanced Endometrial Cancer? An Analysis of the National Cancer Data Base. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e295. DOI: 10.1016/j.ijrobp.2016.06.1366.
- Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data BaseLester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.
- Chapter 45 Intensity Modulated Radiotherapy and Image GuidanceYoung M, Yu J. Chapter 45 Intensity Modulated Radiotherapy and Image Guidance. 2016, 413-426. DOI: 10.1016/b978-0-12-800077-9.00045-1.
- Optimizing a Lupus Autoantibody for Targeted Cancer TherapyNoble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.
- Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic CharacteristicsYoung MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.
- Abstract 4220: A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cellsNoble P, Young M, Weisbart R, Hansen J. Abstract 4220: A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cells. 2014, 4220-4220. DOI: 10.1158/1538-7445.am2014-4220.
- Abstract 654: Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibodyYoung M, Noble P, Weisbart R, Hansen J. Abstract 654: Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibody. 2014, 654-654. DOI: 10.1158/1538-7445.am2014-654.
- A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cellsNoble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.
- Gynecologic CancerYoung M, Higgins S, Yuh W, Mayr N. Gynecologic Cancer. 2013, 185-219. DOI: 10.1007/174_2013_956.
- Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial CancerYoung M, Higgins S, Ratner E, Mani S, Evans S, Silasi D, Azodi M, Rutherford T, Schwartz P, Damast S. Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s447-s448. DOI: 10.1016/j.ijrobp.2012.07.1186.